A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
- Registry ID
- EUCTR2008-000701-11
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Bristol-Myers Squibb International Corporation
- Start date
- 2009-03-12
- Completion date
- 2015-07-31
- Last update
- 2026-08-16
Conditions
- castration-resistant metastatic prostate cancer.
- castration-resistant metastatic prostate cancer
Summary
The primary objective is to compare overall survival for dasatinib plus docetaxel and prednisone versus placebo plus docetaxel and prednisone in subjects with metastatic castration-resistant prostate cancer.
Locations
- , , Hungary
- , , UK
- , , Ireland
- , , Germany
- , , France
- , , Italy
- , , Czechia
- , , Finland
- , , Sweden
- , , Greece
View on source registry